Merck & Co. (MRK)
(Delayed Data from NYSE)
$131.20 USD
+0.48 (0.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $131.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Merck (MRK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$134.59 | $148.00 | $116.00 | 2.96% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Merck comes to $134.59. The forecasts range from a low of $116.00 to a high of $148.00. The average price target represents an increase of 2.96% from the last closing price of $130.72.
Analyst Price Targets (22)
Broker Rating
Merck currently has an average brokerage recommendation (ABR) of 1.26 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 23 brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on 23 recommendations.
Of the 23 recommendations deriving the current ABR, 20 are Strong Buy, representing 86.96% of all recommendations. A month ago, Strong Buy represented 82.61%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 20 | 20 | 19 | 19 | 19 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 1 | 1 | 0 | 0 |
ABR | 1.26 | 1.42 | 1.43 | 1.27 | 1.27 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/8/2024 | Berenberg Bank | Luisa Hector | Strong Buy | Strong Buy |
3/28/2024 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
2/29/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
2/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/29/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
10/27/2023 | BMO Capital Markets | Evan Seigerman | Not Available | Strong Buy |
10/17/2023 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
8/7/2023 | Daiwa America | Narumi Nakagiri | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.26 |
ABR (Last week) | 1.42 |
# of Recs in ABR | 23 |
Average Target Price | $134.59 |
LT Growth Rate | 9.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 198 of 252 |
Current Quarter EPS Est: | 2.16 |